Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS
Category: #health  By Saipriya Iyer  Date: 2020-02-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS

MS (multiple sclerosis) is a serious disease that affects about 1.2 million people across the U.S. and Europe. The ailment is a chronic disease that attacks the CNS (central nervous system). Today, despite present therapies, several MS patients continue to face disability, with one in four of the MS patients suffering from a progressive forms of this disease with no treatments or very limited treatments available. Global pharmaceutical companies are working diligently to find a cure.

A recent effort in this regard came to light when Sanofi, a renowned French pharmaceutical company, reportedly announced that its investigational BTK inhibitor achieved its primary endpoint in the Phase 2b trial. The company’s Bruton's tyrosine kinase (BTK) inhibitor (SAR442168) is a brain-penetrant, oral, and selective small-molecule developed to address multiple sclerosis.

In the Phase 2b study, the BTK inhibitor significantly decreased the disease activity associated with MS, as per measurements done using MRI (magnetic resonance imaging). SAR442168 inhibitor was well tolerated along with no novel safety findings.

The SAR442168 is considered to modulate both innate (CNS microglial cells) and adaptive (B-cell activation) immune cells associated with neuroinflammation in the spinal cord and brain. 

Sanofi’s Global Head of Research and Development, John Reed, M.D., Ph.D. stated that majority of people suffering from MS still endure disability in the course of this disease. The company believes that its BTK inhibitor has the ability to change how multiple sclerosis is treated. This inhibitor might be the first B-cell-targeted MS treatment that hinders the peripheral immune system and crosses the blood-brain barrier to block immune cells that have moved to the brain, while modulating the brain-resident microglia cells which are being implicated in micro sclerosis progression as well.  

Reed further added that building on the company’s heritage in MS, the company is thrilled by these clinical outcomes and looks forward to advance its brain penetrant SAR442168 inhibitor into pivotal clinical studies.

Four Phase 3 studies would further investigate the SAR442168 inhibitor’s effect on multiple sclerosis relapse rates, underlying CNS (central nervous system) damage, and disability progression. Phase 3 studies in progressive and relapsing forms of the MS are scheduled to start during the mid-2020.

Source credit: https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-00-00



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...